These data indicate that NKG2A + NK cells are activated more readily against CLL cells in the presence of XPO1 inhibitors compared to NKG2A- NK cells, however XPO1 inhibition also activates NK cells that are negative for NKG2A, albeit to a lesser extent. The gene discussed is KLRC1; the disease is B-cell chronic lymphocytic leukemia.